Development of a CD123xCD3 bispecific antibody to treat acute myeloid leukemia (AML)

被引：0
|
作者：
Gaudet, Francois
Nemeth, Jennifer F.
McDaid, Ronan
Li, Yingzhe
Harman, Benjamin
Millar, Hillary
Teplyakov, Alexey
Wheeler, John
Luo, Jinquan
Tam, Susan
Wu, Sheng-Jiun
Chen, Emily
Babich, Alexander
Elsayed, Yusri
Attar, Ricardo
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1492
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1492
引用
收藏
页数：3
相关论文
共 50 条
  • [31] VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models
    Stelte-Ludwig, Beatrix
    Clemens, George
    Schomber, Tibor
    Frigault, Melanie M.
    Johnson, Amy J.
    Lerchen, Hans-Georg
    Izumi, Raquel
    Hamdy, Ahmed
    BLOOD, 2022, 140 : 5955 - 5956
  • [32] Characterization of SGN-CD123A, APotent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia
    Li, Fu
    Sutherland, May Kung
    Yu, Changpu
    Walter, Roland B.
    Westendorf, Lori
    Valliere-Douglass, John
    Pan, Lucy
    Cronkite, Ashley
    Sussman, Django
    Klussman, Kerry
    Ulrich, Michelle
    Anderson, Martha E.
    Stone, Ivan J.
    Zeng, Weiping
    Jonas, Mechthild
    Lewis, Timothy S.
    Goswami, Maitrayee
    Wang, Sa A.
    Senter, Peter D.
    Law, Che-Leung
    Feldman, Eric J.
    Benjamin, Dennis R.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (02) : 554 - 564
  • [33] Acute myeloid leukemia (AML) in the elderly. To treat or not to treat: A decision analysis.
    Kusminsky, GD
    Rivas, MM
    O'Flaherty, M
    Maggini, NJ
    Cabarcos, JMP
    Pinto, MT
    BLOOD, 2005, 106 (11) : 230B - 230B
  • [34] Bispecific antibody drug conjugates targeting CD7 and CD33 for the treatment of acute myeloid leukemia
    Bethell, Richard
    Eberlein, Cath
    Pollard, Victoria
    Georgiou, Theonie
    Orphanides, George
    Mooney, Lorraine
    Kendrew, Jane
    Daniels, Tiffany
    CANCER RESEARCH, 2020, 80 (16)
  • [35] Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using Cross-Over-Dual-Variable-Domain (CODV) format for the treatment of acute myeloid leukemia (AML)
    Bonnevaux, Helene
    Guerif, Stephane
    Albrecht, Jana
    Jouannot, Erwan
    Bassinet, Laurent
    Vergezac, Agnes
    Beil, Christian
    Lange, Christian
    Leuschner, Wulf Dirk
    Caron, Anne
    Amara, Celine
    Barriere, Cedric
    Siavellis, Justine
    Bardet, Valerie
    Luna, Ernesto
    Drake, Donald
    Rao, Ercole
    Oprea, Corina
    Wonerow, Peter
    Carrez, Chantal
    Blanc, Veronique
    Hsu, Karl
    Wiederschain, Dmitri
    Fraenkel, Paula G.
    CANCER RESEARCH, 2018, 78 (13)
  • [36] A phase I dose escalating study of infusion of a bispecific antibody (BsAb) for relapsed/refractory acute myeloid leukemia (AML).
    Chen, J
    Bashey, A
    Holman, P
    Carrier, E
    Law, P
    Ball, ED
    BLOOD, 1999, 94 (10) : 227B - 227B
  • [37] CD123 DIAGNOSTIC UTILITY IN ACUTE MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA
    Yang, Wayne
    Loriaux, Marc
    Gatter, Ken
    Braziel, Rita
    Huang, James
    Kelemen, Katalin
    Fan, Guang
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2008, 74B (06) : 376 - 376
  • [38] Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker
    Abdollahpour-Alitappeh, Meghdad
    Razavi-Vakhshourpour, Sepand
    Abolhassani, Mohsen
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2018, 65 (06) : 841 - 847
  • [39] Allogenic T-Cells Targeting CD123 for Adoptive Immunotherapy of Acute Myeloid Leukemia (AML)
    Galetto, Roman
    Lebuhotel, Celine
    Gouble, Agnes
    Schiffer-Mannioui, Cecile
    Smith, Julianne
    BLOOD, 2014, 124 (21)
  • [40] A novel bispecific LILRB4/CD3 antibody with potent killing of monocytic acute myeloid leukemia cells
    Huang, Tao
    Hong, Kyu
    McCutcheon, Krista
    Ma, Jing-Tyan
    Zhu, Ying
    Deng, Mi
    Zhang, Cheng Cheng
    Woodard, Paul
    Xiang, Hong
    Schebye, Xiao Min
    Liao, X. Charlene
    CANCER RESEARCH, 2023, 83 (08)
12345